NEW DATA has shown that concurrent initiation of tirzepatide and biologic therapy is associated with better patient-reported outcomes in obese patients with psoriatic arthritis, with nearly triple the rate of symptom control compared with biologics alone. Biologics and Weight Loss Drugs in Psoriatic ArthritisObesity has been shown to affect up to 45% of patients with psoriatic arthritis and has been independently associated with reduced biologic efficacy and lower rates of minimal disease activity. GLP1s have been recognised to possess immunomodulatory properties beyond metabolic effects, yet their impact on psoriatic arthritis outcomes when combined with biologics has remained largely unknown. Implications for Managing Obesity in Psoriatic Arthritis CareThese findings have suggested that concurrent tirzepatide and biologic initiation in obese patients with psoriatic arthritis is associated with significantly better patient-reported outcomes, skin disease control, and inflammatory markers at six months. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.